|
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C |
Approved |
Circadian gene modulation
|
CLOCK-BMAL1
,
BMAL1 expression (induction)
,
Vitamin D3 receptor
,
Vitamin D binding protein
|
Bmal1,
BMAL1 expression modulation,
BMAL1 expression modulation,
Vitamin D3 receptor, Homeobox protein Hox-A10, Vitamin D-binding protein
|
Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.
|
|
CC(C)CCC1=CC(=C2C=C(C=CC2=C1)OC)CCNC(=O)C |
none |
Phase shifting in humans (via MT1/MT2 receptor activation),
Partial agonist MT2 and associated effects
|
MT2
|
MT2 receptor agonist
|
Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European journal of medicinal chemistry, 49, pp.310-323.
|
|
CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4 |
Not approved |
was found to promote sleep, alter circadian gene expression in the heart, and show a slight trend of increasing free-running periods. Together, these
|
mPer2
,
mPer1
,
Per2 expression
|
Lenghthen the circadian period,
PER gene exspression modulation
|
Han, C., Wirianto, M., Kim, E., Burish, M.J., Yoo, S.H. and Chen, Z., 2021. Clock-modulating activities of the anti-arrhythmic drug moricizine. Clocks & sleep, 3(3), pp.351-365.
|
|
CCC(=O)NCCCC1=C(C=CC(=C1)OC)CC2=CC(=CC=C2)OC |
none |
Full mt2 rexeptor agonist
|
MT2
|
MT2 receptor ligand
|
Hu, Y., Zhu, J., Chan, K.H. and Wong, Y.H., 2013. Development of substituted N-[3-(3-methoxylphenyl) propyl] amides as MT2-selective melatonin agonists: Improving metabolic stability. Bioorganic & medicinal chemistry, 21(2), pp.547-552.
|
|
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O |
Approved |
Oxycodone, like other opioids, can disrupt circadian rhythms, the body's natural 24-hour cycle.
|
Mu opioid receptor
,
OPRK1
|
Mu opioid receptor binding
|
Gulledge, M., Carlezon, W.A. Jr, McHugh, R.K., Kinard, E.A., Prerau, M.J. and Chartoff, E.H., 2025. Spontaneous oxycodone withdrawal disrupts sleep, diurnal, and electrophysiological dynamics in rats. PLoS One, 20(1), p.e0312794.
,
Pierce, B.E., Holter, K., Morton, A., Lekander, A., Bedingham, E., Curry, R. and Gould, R.W., 2022. Effects of oxycodone self-administration on sleep duration and quality in male and female rats. The FASEB Journal, 36(S1), p.R3946.
|
|
CCCC(=O)NCCC1=C2C3=CC=CC=C3CN2C4=C1C=C(C=C4)OC |
none |
significantly reduced NREM sleep onset latency and transiently increased the time spent in NREM sleep, but did not alter REM sleep latency or the amou,
acute sleep-promoting activity
|
MT2
|
Melatonin receptor binding,
MT2 receptor ligand
|
Fisher, S.P. and Sugden, D., 2009. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neuroscience letters, 457(2), pp.93-96.
|
|
C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O1)O |
Approved |
influencing the expression and stability of key circadian clock genes
|
HCN2
,
HCN1
,
CNGA2
,
CNGA3
|
HCN2 activation,
HCN1 activator,
CNGA2 activation,
Affects melatonin synthesis,
CNGA3 activation,
OATP4C1 transportation
|
Levine, J.D., Casey, C.I., Kalderon, D.D. and Jackson, F.R., 1994. Altered circadian pacemaker functions and cyclic AMP rhythms in the Drosophila learning mutant dunce. Neuron, 13(4), pp.967-974.
,
Ono, D., Wang, H., Hung, C.J., Wang, H.T., Kon, N., Yamanaka, A., Li, Y. and Sugiyama, T., 2023. Network-driven intracellular cAMP coordinates circadian rhythm in the suprachiasmatic nucleus. Science Advances, 9(1), p.eabq7032.
,
O'Neill, J.S. and Reddy, A.B., 2012. The essential role of cAMP/Ca2+ signalling in mammalian circadian timekeeping.
|
|
CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O |
Approved |
Circadian rhythm disruption
|
CLOCK-BMAL1
,
BMAL1 expression (induction)
,
Dec1 gene expression
|
Bmal1,
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation,
by an immediate-early induction of Dec1
|
Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.
,
Chen, S.J., Yu, F., Feng, X., Li, Q., Jiang, Y.H., Zhao, L.Q., Cheng, P.P., Wang, M., Song, L.J., Liang, L.M. and He, X.L., 2024. DEC1 is involved in circadian rhythm disruption-exacerbated pulmonary fibrosis. Cell Communication and Signaling, 22(1), p.245.
|
|
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3 |
Approved |
Circadian entrainment of activity episodes
|
Mu opioid receptor
,
OPRK1
,
OPRD1
|
Mu opioid receptor binding,
Kappa opioid receptor binding,
delta opioid receptor binding
|
Du, K., Shi, Q., Zhou, X., Zhang, L., Su, H., Zhang, C., Wei, Z., Liu, T., Wang, L., Wang, X., Cong, B. and Yun, K., 2024. Melatonin attenuates fentanyl-induced behavioral sensitization and circadian rhythm disorders in mice. Physiology & Behavior, 279, p.114523
,
Gillman, A.G., Leffel, J.K. 2nd, Kosobud, A.E. and Timberlake, W., 2009. Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals. Behavioural Brain Research, 205(1), pp.102–114.
|
|
CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O |
Approved |
Disrupts sleep
|
Corticosteroid hormone receptor
|
Affects melatonin synthesis,
Melatonin synthesis alteration,
Corticosteroid Hormone Receptor Agonist,
Glucocorticoid Signaling
|
Jiang, Y., Gen, N., Wang, P., Feng, N. and Lu, X., 2022. Prednisolone induces sleep disorders via inhibition of melatonin secretion by the circadian rhythm in zebrafish. Biomedicine & Pharmacotherapy, 147, p.112590.
|
|
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC |
Approved |
Period lengthening in human cells
|
CLOCK-BMAL1
|
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation,
mTOR signaling inhibition
|
Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.
|
|
CC(C)C1=C(C(=CC=C1)C(C)C)O |
Approved |
Phase advance
|
GABAA receptors
|
GABA A receptor binding
|
Challet, E., Gourmelen, S., Pevet, P., Oberling, P. and Pain, L., 2007. Reciprocal relationships between general (propofol) anesthesia and circadian time in rats. Neuropsychopharmacology, 32(3), pp.728–735.
,
Bienert, A., Kusza, K., Wawrzyniak, K., Grześkowiak, E., Kokot, Z.J., Matysiak, J., Grabowski, T., Wolc, A., Wiczling, P. and Regulski, M., 2010. Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients. Journal of Pharmacokinetics and Pharmacodynamics, 37, pp.289–304.
,
Touitou, Y., Mauvieux, B., Reinberg, A. and Dispersyn, G., 2016. Disruption of the circadian period of body temperature by the anesthetic propofol. Chronobiology International, 33(9), pp.1247–1254.
|
|
CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O |
Not approved |
restores normal circadian rhythms,
MT1 agonist with poorly described
|
MT1
|
selective MT1A receptor agonist
|
Jockers, R., Delagrange, P., Dubocovich, M.L., Markus, R.P., Renault, N., Tosini, G., Cecon, E. and Zlotos, D.P., 2016. Update on melatonin receptors: IUPHAR Review 20. British Journal of Pharmacology, 173(18), pp.2702–2725.
|
|
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C |
Approved |
Resetting of circadian time in peripheral tissues
|
Corticosteroid hormone receptor
|
Corticosteroid Hormone Receptor Agonist,
Glucocorticoid Signaling
|
Barnea, M., Madar, Z. and Froy, O., 2013. Dexamethasone induces high-amplitude rhythms in preadipocytes, but hinders circadian expression in differentiated adipocytes. Chronobiology International, 30(6), pp.837-842.
,
Balsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schutz, G. and Schibler, U., 2000. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science, 289(5488), pp.2344-2347.
|
|
CNC1(CCCCC1=O)C2=CC=CC=C2Cl |
Approved |
Modulation of circadian gene expression and CLOCK:BMAL1 transcriptional activity in neuronal cells and rats
|
CLOCK-BMAL1
|
Core clock modulation
|
Bellet, M.M., Vawter, M.P., Bunney, B.G., Bunney, W.E. and Sassone-Corsi, P., 2011. Ketamine influences CLOCK:BMAL1 function leading to altered circadian gene expression. PLoS One, 6(8), p.e23982.
,
Zhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., Xu, Y. and Wang, W., 2019. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: a protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Brain and Behavior, 9(11), p.e01423
,
Mihara, T., Kikuchi, T., Kamiya, Y., Koga, M., Uchimoto, K., Kurahashi, K. and Goto, T., 2012. Day or night administration of ketamine and pentobarbital differentially affect circadian rhythms of pineal melatonin secretion and locomotor activity in rats. Anesthesia & Analgesia, 115(4), pp.805–813.
|
|
CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl |
Approved |
helps with sleep, it doesn't necessarily reset or re-establish the body's internal clock
|
Unknown
|
Sleep promotion
|
Krystal, A.D., Walsh, J.K., Laska, E., Caron, J., Amato, D.A., Wessel, T.C. and Roth, T., 2003. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26(7), pp.793-799.
|
|
CC(=O)NCCC1=C(CC2=C1C3=C(C=C2)OCC3)CC4CCCCC4 |
Not approved |
Discrupts temporal organization in Candida albicans,
Full mt2 rexeptor agonist
|
MT2
|
MT2 receptor agonist,
MT2 receptor ligand
|
Koike, T., Hoashi, Y., Takai, T., Nakayama, M., Yukuhiro, N., Ishikawa, T., Hirai, K. and Uchikawa, O., 2011. 1, 6-Dihydro-2 H-indeno [5, 4-b] furan Derivatives: Design, Synthesis, and Pharmacological Characterization of a Novel Class of Highly Potent MT2-Selective Agonists. Journal of medicinal chemistry, 54(9), pp.3436-3444.
|
|
CC1=CC(=C2C=C(C=C(C2=N1)F)F)NC(=O)NC3=CC=C(C=C3)N(C)C |
Not approved |
can attenuate the sleep-promoting effects of the OX2R antagonist
|
orexin receptor subtypes (OX1 and OX2)
|
OX₁R Antagonism
|
Morairty, S.R., Revel, F.G., Malherbe, P., Moreau, J.L., Valladao, D., Wettstein, J.G., Kilduff, T.S. and Borroni, E., 2012. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PloS one, 7(7), p.e39131.
|
|
COC1=CC2=C(C=CC=C2CCNC(=O)C(F)F)C=C1 |
Not approved |
MT1 agonist with poorly described,
increases the amplitude of circadian rhythm activity in mice with corticosterone-induced depression/anxiety
|
MT1
|
MT1 receptor binding
|
Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European journal of medicinal chemistry, 49, pp.310-323.
|
|
CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.[Cl-].[Cl-] |
Approved |
Modulation of circadian gene expression in human U2OS cells
|
CLOCK-BMAL1
|
Bmal1,
BMAL1 expression modulation
|
Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.
|
|
ClC=1C=C(C=CC1Cl)N1C(NC2=C(C1=O)C=NN2C2=CC=CC=C2)=O |
none |
reduces the levels of PRR7 protein in Arabidopsis
|
CCA1
|
PRR
|
Uehara, T.N., Takao, S., Matsuo, H., Saito, A.N., Ota, E., Ono, A., Itami, K., Kinoshita, T., Yamashino, T., Yamaguchi, J. and Nakamichi, N., 2023. A Small-Molecule Modulator Affecting the Clock-Associated PSEUDO-RESPONSE REGULATOR 7 Amount. Plant And Cell Physiology, 64(11), pp.1397-1406.
|
|
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42 |
Approved |
restores normal circadian rhythms
|
5-HT7
|
5-HT7 binding
|
Wirz-Justice, A., Werth, E., Savaskan, E., Knoblauch, V., Gasio, P.F. and Müller-Spahn, F., 2000. Haloperidol disrupts, clozapine reinstates the circadian rest–activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Disease & Associated Disorders, 14(4), pp.212-215.
|
|
CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O |
Approved |
effects on the circadian rhythm, also known as the body's natural sleep-wake cycle, are primarily related to its drowsiness and sedation properties
|
Histamine 1 receptor
|
Histamine 1 blocker
|
Ward, L.G., Bourjeily, G., Guthrie, K., Salmoirago-Blotcher, E., Sharp, M., Desmarattes, A. and Bublitz, M., 2024. Sleep Quality in High-Risk Pregnancies: Mixed Methods Results from a Randomized Controlled Trial of a Mindfulness Training Intervention. Journal of Integrative and Complementary Medicine, 30(10), pp.953-960.
|
|
CC(C)(C)OC(=O)CC1=CC(=C(C=C1CC2=CC(=C(C=C2[125I])OC)OC)OC)OC |
None |
MT2 antagonist; disrupts melatonin signaling (in human receptor models),
Partial agonist MT2 and associated effects
|
MT2
|
MT2 receptor ligand
|
Legros, C., Brasseur, C., Delagrange, P., Ducrot, P., Nosjean, O. and Boutin, J.A., 2016. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. The Journal of Pharmacology and Experimental Therapeutics, 356(3), pp.681-692.
,
Legros, C., Matthey, U., Grelak, T., Pedragona-Moreau, S., Hassler, W., Yous, S., Thomas, E., Suzenet, F., Folleas, B., Lefoulon, F. and Berthelot, P., 2013. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. International journal of molecular sciences, 14(5), pp.8948-8962.
|
|
(B. bifidum W23, B. lactis W51, B. lactis W52) and lactobacilli (L. acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, L. lactis W19) |
Not approved |
restores normal circadian rhythms
|
CLOCK-BMAL1
,
Arntl (gene)
,
NPAS2
,
BMAL1 expression (induction)
,
TIMELESS
|
Core clock modulation,
Bmal1,
Activation of CLOCK/Bmal1 mediated transcription,
Circadian Clock Impact,
TIMELESS
|
Kreuzer, K., Birkl-Toeglhofer, A.M., Haybaeck, J., Reiter, A., Dalkner, N., Fellendorf, F.T., Maget, A., Platzer, M., Seidl, M., Mendel, L.M. and Lenger, M., 2024. PROVIT-CLOCK: A Potential Influence of Probiotics and Vitamin B7 Add-On Treatment and Metabolites on Clock Gene Expression in Major Depression. Neuropsychobiology, 83(3-4), pp.135-151.
|